Accesswire
29 Sept 2026, 12:45 UTC · 3h ago
Verdict
Headline takes no side. We score NNVC +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 89% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish · 2 new · 1 priced in
NanoViricides began enrollment for Phase II clinical trials of NV-387 for both Mpox and Ebola virus disease at the end of September 2026.
Newfiled Annual Report on September 28, 2026
So whatSuccessful Phase II data in the next 6-12 months could trigger fast-track regulatory pathways given the lack of approved Ebola treatments.
More positive than 93% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
The US FDA granted Orphan Drug Designation and Rare Pediatric Disease Drug designation for NV-387 as a Measles treatment in May and June 2026.
Priced inoccurred May and June 2026
More positive than 79% of claims this week
The Ebola Bundibugyo virus outbreak in DRC grew from 4,945 confirmed cases on August 14 to 7,890 cases by September 23, 2026.
NewWHO daily report cited in Sep 29 filing
So whatThe 60% increase in cases over 40 days accelerates the patient recruitment timeline for the Phase II trial started this month.
More positive than 67% of claims this week
Which stocks this story touches
More positive than 89% of ticker scores this week
The company has successfully advanced its NV-387 drug into Phase II trials for Mpox and Ebola, and received FDA Orphan Drug and Rare Pediatric Disease designations for Measles.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
4h ago
−4.0%
Price is moving against the score
$1.44 vs $1.50 close before publication (Sep 28) · not market-adjusted
NNVC chart →
